Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

Also called NCT05666128

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
  • Hyundai Pharm Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05666128
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05666128. Randomized; double masking; primary purpose treatment. Start 2022-06-17 (actual); primary completion 2023-06-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
HD-6277
Intervention (Drug)
HD-6277
Intervention (Drug)
Placebo
Lead sponsor
Hyundai Pharm (class: industry)

Record details

Record id
cardio:ct-nct05666128
Content hash
8e53293d9477fe4ab6c7a33554226290d638e869cfc79a515ac9bfd3a45cd659